sulfasalazine has been researched along with Bladder Cancer in 6 studies
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Sulfasalazine (SSZ), a drug used in the treatment of rheumatoid arthritis (RA), inhibits glutamate-cystine transport, and suppressed CD44v-dependent tumor growth and increased sensitivity to cytotoxic drugs in an in vivo study." | 3.83 | Potential of sulfasalazine as a therapeutic sensitizer for CD44 splice variant 9-positive urogenital cancer. ( Kubo, T; Morikawa, A; Morita, T; Nagano, O; Saya, H; Takayama, T, 2016) |
| "The patient was diagnosed with reactive arthritis associated with BCG intravesical injection therapy, as three typical symptoms were observed (bilateral conjunctivitis, urethritis, polyarthritis)." | 1.72 | [A Case of Reactive Arthritis after BCG Intravesical Infusion Therapy Successfully Treated with Salazosulfapyridine]. ( Endo, T; Ishitsuka, R; Kinase, S; Oguni, H; Takahashi, R; Tsutsumi, M; Yanagihashi, R, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Takahashi, R | 1 |
| Kinase, S | 1 |
| Yanagihashi, R | 1 |
| Ishitsuka, R | 1 |
| Endo, T | 1 |
| Oguni, H | 1 |
| Tsutsumi, M | 1 |
| Ogihara, K | 1 |
| Kikuchi, E | 1 |
| Okazaki, S | 1 |
| Hagiwara, M | 1 |
| Takeda, T | 1 |
| Matsumoto, K | 1 |
| Kosaka, T | 1 |
| Mikami, S | 1 |
| Saya, H | 2 |
| Oya, M | 1 |
| Ye, P | 1 |
| Mimura, J | 1 |
| Okada, T | 1 |
| Sato, H | 1 |
| Liu, T | 1 |
| Maruyama, A | 1 |
| Ohyama, C | 1 |
| Itoh, K | 1 |
| Takayama, T | 1 |
| Kubo, T | 1 |
| Morikawa, A | 1 |
| Morita, T | 1 |
| Nagano, O | 1 |
| Espin Jaime, MT | 1 |
| Moran Penco, JM | 1 |
| Garcia Agundez, JA | 1 |
| Caballero Loscos, MJ | 1 |
| Sanjuan Rodriguez, S | 1 |
| Botello Martinez, F | 1 |
| Gomez de Tbjada, R | 1 |
| Laguna Alvarez, E | 1 |
| Benitez Rodriguez, I | 1 |
| Filiadis, IF | 1 |
| Georgiou, IA | 1 |
| Giannakopoulos, X | 1 |
6 other studies available for sulfasalazine and Bladder Cancer
| Article | Year |
|---|---|
[A Case of Reactive Arthritis after BCG Intravesical Infusion Therapy Successfully Treated with Salazosulfapyridine].
Topics: Administration, Intravesical; Aged; Arthritis, Reactive; BCG Vaccine; Carcinoma, Transitional Cell; | 2022 |
Sulfasalazine could modulate the CD44v9-xCT system and enhance cisplatin-induced cytotoxic effects in metastatic bladder cancer.
Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation | 2019 |
Nrf2- and ATF4-dependent upregulation of xCT modulates the sensitivity of T24 bladder carcinoma cells to proteasome inhibition.
Topics: Activating Transcription Factor 4; Amino Acid Transport System y+; Antineoplastic Agents; Boronic Ac | 2014 |
Potential of sulfasalazine as a therapeutic sensitizer for CD44 splice variant 9-positive urogenital cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arthritis, Rheumatoid; Humans; Hyaluronan Rece | 2016 |
Urinary bladder cancer in a girl with a slow-acetylator genotype and treated with sulphasalazine.
Topics: Acetyltransferases; Antineoplastic Agents; Carcinoma, Papillary; Child; Female; Humans; Phenotype; S | 1997 |
Urinary bladder cancer in a girl with a slow-acetylator genotype and treated with sulphasalazine.
Topics: Acetylation; Anti-Inflammatory Agents; Female; Humans; Phenotype; Sulfasalazine; Urinary Bladder Neo | 1998 |